210 related articles for article (PubMed ID: 11887965)
1. Pharmacogenetics and antiepileptic drugs.
Spear BB
Epilepsia; 2001; 42 Suppl 5():31-4. PubMed ID: 11887965
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs.
Anderson GD
Ther Drug Monit; 2008 Apr; 30(2):173-80. PubMed ID: 18367977
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.
Seo T; Ishitsu T; Ueda N; Nakada N; Yurube K; Ueda K; Nakagawa K
Pharmacogenomics; 2006 Jun; 7(4):551-61. PubMed ID: 16753003
[TBL] [Abstract][Full Text] [Related]
4. The interface of preclinical evaluation with clinical testing of antiepileptic drugs: role of pharmacogenomics and pharmacogenetics.
Holmes GL
Epilepsy Res; 2002 Jun; 50(1-2):41-54. PubMed ID: 12151116
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms Affecting the Response to Novel Antiepileptic Drugs.
Urzì Brancati V; Pinto Vraca T; Minutoli L; Pallio G
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768858
[TBL] [Abstract][Full Text] [Related]
6. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.
Klotz U
Clin Pharmacokinet; 2007; 46(4):271-9. PubMed ID: 17375979
[TBL] [Abstract][Full Text] [Related]
7. The potential of pharmacogenetics in the treatment of epilepsy.
Depondt C
Eur J Paediatr Neurol; 2006 Mar; 10(2):57-65. PubMed ID: 16531088
[TBL] [Abstract][Full Text] [Related]
8. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
Taur SR; Kulkarni NB; Gandhe PP; Thelma BK; Ravat SH; Gogtay NJ; Thatte UM
J Postgrad Med; 2014; 60(3):265-9. PubMed ID: 25121365
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and the treatment of epilepsy: what do we know?
Božina N; Sporiš IŠ; Božina T; Klarica-Domjanović I; Tvrdeić A; Sporiš D
Pharmacogenomics; 2019 Oct; 20(15):1093-1101. PubMed ID: 31588875
[TBL] [Abstract][Full Text] [Related]
10. Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy.
Orlandi A; Paolino MC; Striano P; Parisi P
Expert Opin Drug Metab Toxicol; 2018 May; 14(5):505-512. PubMed ID: 29804481
[TBL] [Abstract][Full Text] [Related]
11. Antiepileptic drug pharmacogenetics.
Patsalos PN
Ther Drug Monit; 2000 Feb; 22(1):127-30. PubMed ID: 10688275
[TBL] [Abstract][Full Text] [Related]
12. The clinical impact of pharmacogenetics on the treatment of epilepsy.
Löscher W; Klotz U; Zimprich F; Schmidt D
Epilepsia; 2009 Jan; 50(1):1-23. PubMed ID: 18627414
[TBL] [Abstract][Full Text] [Related]
13. The pharmacogenomics of epilepsy.
Franco V; Perucca E
Expert Rev Neurother; 2015 Oct; 15(10):1161-70. PubMed ID: 26327193
[TBL] [Abstract][Full Text] [Related]
14. The role of common variation in drug transporter genes in refractory epilepsy.
Soranzo N; Goldstein DB; Sisodiya SM
Expert Opin Pharmacother; 2005 Jul; 6(8):1305-12. PubMed ID: 16013981
[TBL] [Abstract][Full Text] [Related]
15. Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis.
Chouchi M; Kaabachi W; Klaa H; Tizaoui K; Turki IB; Hila L
BMC Neurol; 2017 Feb; 17(1):32. PubMed ID: 28202008
[TBL] [Abstract][Full Text] [Related]
16. [Personalized medicine for epilepsy based on the pharmacogenomic testing].
Yoshida S; Sugawara T; Nishio T; Kaneko S
Brain Nerve; 2011 Apr; 63(4):295-9. PubMed ID: 21441631
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.
López M; Dorado P; Monroy N; Alonso ME; Jung-Cook H; Machín E; Peñas-Lledó E; Llerena A
Drug Metabol Drug Interact; 2011; 26(1):5-12. PubMed ID: 21557672
[TBL] [Abstract][Full Text] [Related]
18. [Epilepsy pharmacogenetics : science or fiction?].
Depondt C
Med Sci (Paris); 2013 Feb; 29(2):189-93. PubMed ID: 23452606
[TBL] [Abstract][Full Text] [Related]
19. Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications.
Depondt C; Shorvon SD
Pharmacogenomics; 2006 Jul; 7(5):731-45. PubMed ID: 16886898
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
